COMMUNIQUÉS West-GlobeNewswire

AOByte Works with eLabNext to Streamline Custom Add-On Development

05/09/2024 - 11:20

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Today, eLabNext , a company that provides digital solutions for the collection, management, and analysis of laboratory information, announced a new collaboration with AOByte , [...]

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

05/09/2024 - 10:22

COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 7,164,460 as a consequence of employees’ exercise of warrants [...]

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule

05/09/2024 - 10:00

STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major [...]

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

05/09/2024 - 10:00

STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non- [...]

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

05/09/2024 - 10:00

New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities MELBOURNE, Australia, Sept [...]

Trading in GN Store Nord shares by board members, executives and associated persons

05/09/2024 - 09:12

Trading in GN Store Nord shares by board members, executives and associated persons GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to [...]

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe

05/09/2024 - 08:35

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The European Commission’s decision to revoke the OCALIVA® conditional [...]

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

05/09/2024 - 08:00

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc ( [...]

Statement re Change of Corporate Adviser

05/09/2024 - 08:00

DXS INTERNATIONAL PLC (AQSE: DXSP) Change of Adviser DXS International plc (AQSE: DXSP) ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that it has appointed Hybridan LLP [...]

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

05/09/2024 - 07:00

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Halle (Saale) / Munich, Germany, September 5 , 2024 - Vivoryon Therapeutics N.V. ( [...]

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

05/09/2024 - 05:58

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 00:42

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today [...]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/09/2024 - 22:49

SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Sotera Health Announces Secondary Offering of Common Stock

04/09/2024 - 22:41

CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $ [...]

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

04/09/2024 - 22:30

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117 [...]

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 22:30

Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a [...]

DBV Technologies participera à la 26e conférence annuelle H.C. Wainwright Global Investment

04/09/2024 - 22:30

Châtillon, France, 4 septembre, 2024 (22:30 CET) DBV Technologies participera à la 26e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

04/09/2024 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 sept. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Monthly information on share capital and company voting rights

04/09/2024 - 22:30

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]